MG
Montreal Gazette
›Mosaic Therapeutics appoints Dr Vince O’Neill, MD, as Head of R&D›Anfield Energy Further Amends Credit Facility with Extract›Todd: Clueless Leafs blinded by headlight of Canadiens’ playoff train›Heidelberg Materials North America completes acquisition of BURNCO’s Edmonton assets›XORTX Confirms Effective Date of Share Consolidation›AGI Announces AGM Date and Responds to Plantro News Release›Greenland Resources Signs Eight Year Off-take Agreement With SSAB to Supply High Quality Molybdenum›Direct Energy Regulated Services Announces Natural Gas Rates for April 2026›Ripple Treasury Launches the First Treasury Management System (TMS) with Native Digital Asset Capabilities›Royal Yacht International Announces Strategic Relationship with Douglas Elliman to Power Global Yacht Sales and Charter Through Elliman Yachts›TimeSmartAI Inc. Secures Strategic Investment to Scale Physician Contract Compliance Infrastructure for Leading Healthcare Systems›Real Matters to Announce Second Quarter Fiscal 2026 Financial Results on May 1, 2026›Vancity reports strong 2025 performance. Asset levels reach a record $41 billion›Bitget Expands Agent Hub Ecosystem Through MuleRun Partnership to Advance Agentic Trading›The Critical Metals No One Can Replace Are Running Out of Inventory›Fleming College Launches Entrance Scholarships to Support Student Success and Workforce Needs›Parents relieved after crossing guard assigned near Montreal West train station›About Last Night: Canadiens show grit in possible playoff preview›Letters: The overriding question about the override clause›AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure
Last updated: May 3, 2026, 11:00 a.m.